Comparing Antibody-Drug Conjugates for Metastatic Breast Cancer
Results favor Enhertu for treating metastatic breast cancer that recurs or does not respond to first-line treatment.
Progress Against Cancer
Results favor Enhertu for treating metastatic breast cancer that recurs or does not respond to first-line treatment.
Metastatic cancer patients nearing death continue to receive high-dose radiation despite guidelines advising against it, and new standards are likely to reduce racial disparities in lung cancer screening.
Each year in the United States, about 14,480 women are diagnosed with cervical cancer, and about 4,290 women die of the disease. Survivors often face a lifetime of complications, from infertility to pain and bleeding. ...
Women with breast cancer who choose fertility preservation have treatment outcomes similar to women who don’t undergo fertility preservation.
Researchers aim to minimize disease relapses by targeting multiple proteins.
The year 2021 defied our expectations in a variety of ways. The delta and omicron COVID-19 variants imposed unprecedented challenges on the health care system and threatened our hopes of an end to the...
Patient expenses for cancer care exceed $21 billion in 2019, the FDA introduces stringent requirements for breast implants and more news of the week from Cancer Today.
Liver cancer is the second most common cause of cancer-related deaths worldwide. In 2021, it is estimated that more than 42,000 people will be diagnosed with the disease and approximately 30,000 will die because...
On Wednesday, the American Association for Cancer Research (AACR) released its annual Cancer Progress Report. Now in its 11th year, the report details advances in the cancer research continuum, provides a comprehensive review of anticancer drugs, diagnostic tools, and devices approved by the U.S. Food and Drug Administration in the past year, shines a...
study shows the cost of drugs that manage cancer-related symptoms adds up, and more news of the week from Cancer Today magazine.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now